Clinical Trial

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

Study acronym: VAC087
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-12; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-03-09
Trial Details
NCT Number NCT07183371
Lead Sponsor University of Oxford
Collaborators: Institut de Recherche en Sciences de la Sante, Burkina Faso, European and Developing Countries Clinical Trials Partnership (EDCTP), European Vaccine Initiative, Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)
Conditions Malaria,Falciparum
Enrollment 360 participants
Start Date 2025-12-15
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-11